Adagio Medical Holdings, Inc (ADGM)

Adagio Medical Holdings, Inc. is a medical device company developing catheter-based ablation technologies for heart rhythm disorders. Its platform uses ultra-low temperature cryoablation, which freezes targeted cardiac tissue to create lesions that block the abnormal electrical signals behind arrhythmias.

The company's main focus is ventricular tachycardia, a dangerous rapid heartbeat originating in the heart's lower chambers, for which it has developed a dedicated cryoablation catheter and system. It has also developed technology for treating atrial fibrillation. Adagio Medical sells to hospitals and electrophysiology labs and is headquartered in Laguna Hills, California. It became publicly traded on Nasdaq in 2024 through a merger with a special purpose acquisition company.